[{"orgOrder":0,"company":"Sinopharm","sponsor":"ChromaDex, Inc","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Nicotinamide Riboside","moa":"NAD","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Sinopharm","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sinopharm \/ ChromaDex, Inc","highestDevelopmentStatusID":"15","companyTruncated":"Sinopharm \/ ChromaDex, Inc"},{"orgOrder":0,"company":"University of Oklahoma","sponsor":"University of Pennsylvania | Oklahoma Medical Research Foundation | Elysium Health","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nicotinamide Riboside","moa":"NAD","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"University of Oklahoma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"University of Oklahoma \/ University of Pennsylvania | Oklahoma Medical Research Foundation | Elysium Health","highestDevelopmentStatusID":"11","companyTruncated":"University of Oklahoma \/ University of Pennsylvania | Oklahoma Medical Research Foundation | Elysium Health"},{"orgOrder":0,"company":"University of Copenhagen","sponsor":"Bispebjerg Hospital | Elysium Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Nicotinamide Riboside","moa":"NAD","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"University of Copenhagen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"University of Copenhagen \/ Bispebjerg Hospital | Elysium Health","highestDevelopmentStatusID":"8","companyTruncated":"University of Copenhagen \/ Bispebjerg Hospital | Elysium Health"},{"orgOrder":0,"company":"Oslo University Hospital","sponsor":"Haukeland University Hospital | South-Eastern Norway Regional Health Authority | Klinbeforsk | The Dam Foundation | Elysium Health | NKS Olaviken Gerontopsychiatric Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Nicotinamide Riboside","moa":"NAD","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Oslo University Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oslo University Hospital \/ Haukeland University Hospital | South-Eastern Norway Regional Health Authority | Klinbeforsk | The Dam Foundation | Elysium Health | NKS Olaviken Gerontopsychiatric Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Oslo University Hospital \/ Haukeland University Hospital | South-Eastern Norway Regional Health Authority | Klinbeforsk | The Dam Foundation | Elysium Health | NKS Olaviken Gerontopsychiatric Hospital"},{"orgOrder":0,"company":"University of South Alabama","sponsor":"Elysium Health","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Nicotinamide Riboside","moa":"NAD","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Undisclosed","graph3":"University of South Alabama","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"University of South Alabama \/ Elysium Health","highestDevelopmentStatusID":"1","companyTruncated":"University of South Alabama \/ Elysium Health"},{"orgOrder":0,"company":"University of Copenhagen","sponsor":"Bispebjerg Hospital | Elysium Health","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Nicotinamide Riboside","moa":"NAD","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"University of Copenhagen","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"University of Copenhagen \/ Bispebjerg Hospital | Elysium Health","highestDevelopmentStatusID":"1","companyTruncated":"University of Copenhagen \/ Bispebjerg Hospital | Elysium Health"},{"orgOrder":0,"company":"Mayo Clinic","sponsor":"Elysium Health","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Nicotinamide Riboside","moa":"NAD","graph1":"Undisclosed","graph2":"Phase II","graph3":"Mayo Clinic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mayo Clinic \/ Elysium Health","highestDevelopmentStatusID":"8","companyTruncated":"Mayo Clinic \/ Elysium Health"},{"orgOrder":0,"company":"University of Copenhagen","sponsor":"Elysium Health","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nicotinamide Riboside","moa":"NAD","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"University of Copenhagen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Copenhagen \/ Elysium Health","highestDevelopmentStatusID":"8","companyTruncated":"University of Copenhagen \/ Elysium Health"},{"orgOrder":0,"company":"Akershus University Hospital","sponsor":"ChromaDex, Inc | Norwegian Cancer Society | Norwegian Breast Cancer Association | Helse S\u00f8r-\u00d8st","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Nicotinamide Riboside","moa":"NAD","graph1":"Oncology","graph2":"Phase II","graph3":"Akershus University Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Akershus University Hospital \/ ChromaDex, Inc | Norwegian Cancer Society | Norwegian Breast Cancer Association | Helse S\u00f8r-\u00d8st","highestDevelopmentStatusID":"8","companyTruncated":"Akershus University Hospital \/ ChromaDex, Inc | Norwegian Cancer Society | Norwegian Breast Cancer Association | Helse S\u00f8r-\u00d8st"},{"orgOrder":0,"company":"Haukeland University Hospital","sponsor":"Oslo University Hospital | Akershus Universitetssykehus HF | Vestre Viken Hospital Trust | Sykehuset Ostfold | Nevro Arendal AS | Helse Forde | Helse Fonna | Universitetssykehuset Nord Norge HF | Helse M\u00f8re og Romsdal HF | Nordlandssykehuset HF | Elysium ","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Nicotinamide Riboside","moa":"NAD","graph1":"Neurology","graph2":"Phase II","graph3":"Haukeland University Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Haukeland University Hospital \/ Oslo University Hospital | Akershus Universitetssykehus HF | Vestre Viken Hospital Trust | Sykehuset Ostfold | Nevro Arendal AS | Helse Forde | Helse Fonna | Universitetssykehuset Nord Norge HF | Helse M\u00f8re og Romsdal HF | Nordlandssykehuset HF | Elysium ","highestDevelopmentStatusID":"8","companyTruncated":"Haukeland University Hospital \/ Oslo University Hospital | Akershus Universitetssykehus HF | Vestre Viken Hospital Trust | Sykehuset Ostfold | Nevro Arendal AS | Helse Forde | Helse Fonna | Universitetssykehuset Nord Norge HF | Helse M\u00f8re og Romsdal HF | Nordlandssykehuset HF | Elysium "},{"orgOrder":0,"company":"Akershus University Hospital","sponsor":"The Bergesen Foundation | South-Eastern Norway Regional Health Authority | Sykehuset Innlandet HF | Oslo University Hospital | St. Olavs Hospital | Haukeland University Hospital | University Hospital of North Norway | University of Bergen","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Nicotinamide Riboside","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Akershus University Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Akershus University Hospital \/ The Bergesen Foundation | South-Eastern Norway Regional Health Authority | Sykehuset Innlandet HF | Oslo University Hospital | St. Olavs Hospital | Haukeland University Hospital | University Hospital of North Norway | University of Bergen","highestDevelopmentStatusID":"8","companyTruncated":"Akershus University Hospital \/ The Bergesen Foundation | South-Eastern Norway Regional Health Authority | Sykehuset Innlandet HF | Oslo University Hospital | St. Olavs Hospital | Haukeland University Hospital | University Hospital of North Norway | University of Bergen"},{"orgOrder":0,"company":"Haukeland University Hospital","sponsor":"Elysium Health","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Nicotinamide Riboside","moa":"NAD","graph1":"Neurology","graph2":"Undisclosed","graph3":"Haukeland University Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Haukeland University Hospital \/ Elysium Health","highestDevelopmentStatusID":"1","companyTruncated":"Haukeland University Hospital \/ Elysium Health"},{"orgOrder":0,"company":"Mayo Clinic","sponsor":"HealthTech Connex Inc. | Thorne HealthTech","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Nicotinamide Riboside","moa":"NAD","graph1":"Undisclosed","graph2":"Phase II","graph3":"Mayo Clinic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mayo Clinic \/ HealthTech Connex Inc. | Thorne HealthTech","highestDevelopmentStatusID":"8","companyTruncated":"Mayo Clinic \/ HealthTech Connex Inc. | Thorne HealthTech"},{"orgOrder":0,"company":"Haukeland University Hospital","sponsor":"Elysium Health","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Nicotinamide Riboside","moa":"NAD","graph1":"Neurology","graph2":"Undisclosed","graph3":"Haukeland University Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Haukeland University Hospital \/ Elysium Health","highestDevelopmentStatusID":"1","companyTruncated":"Haukeland University Hospital \/ Elysium Health"},{"orgOrder":0,"company":"Charite University, Berlin, Germany","sponsor":"ChromaDex, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Dietary Supplement","year":"2023","type":"Inapplicable","leadProduct":"Nicotinamide Riboside","moa":"NAD","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Charite University, Berlin, Germany","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Charite University, Berlin, Germany \/ ChromaDex, Inc","highestDevelopmentStatusID":"1","companyTruncated":"Charite University, Berlin, Germany \/ ChromaDex, Inc"},{"orgOrder":0,"company":"Mayo Clinic","sponsor":"Sanford Health","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Nicotinamide Riboside","moa":"NAD","graph1":"Undisclosed","graph2":"Phase II","graph3":"Mayo Clinic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mayo Clinic \/ Sanford Health","highestDevelopmentStatusID":"8","companyTruncated":"Mayo Clinic \/ Sanford Health"},{"orgOrder":0,"company":"Nutraceuticals Research Institute","sponsor":"ChromaDex, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Dietary Supplement","year":"2025","type":"Inapplicable","leadProduct":"Nicotinamide Riboside","moa":"NAD","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Nutraceuticals Research Institute","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nutraceuticals Research Institute \/ ChromaDex, Inc","highestDevelopmentStatusID":"1","companyTruncated":"Nutraceuticals Research Institute \/ ChromaDex, Inc"}]
Find Clinical Drug Pipeline Developments & Deals for Nicotinamide Riboside
Sponsor :
Haukeland University Hospital | South-Eastern Norway Regional Health Authority | Klinbeforsk | The Dam Foundation | Elysium Health | NKS Olaviken Gerontopsychiatric Hospital
Sponsor :
Haukeland University Hospital | South-Eastern Norway Regional Health Authority | Klinbeforsk | The Dam Foundation | Elysium Health | NKS Olaviken Gerontopsychiatric Hospital
Details :
Tru Niagen®, featuring Niagen®, is one of the top-selling brands in the Vitamin B3 category on Amazon U.S. for boosting NAD+ levels. Supplementation with Niagen® is backed by 20 published and peer-reviewed clinical trials.
Reset All
